WO2005044186A3 - Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same - Google Patents

Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same Download PDF

Info

Publication number
WO2005044186A3
WO2005044186A3 PCT/US2004/035068 US2004035068W WO2005044186A3 WO 2005044186 A3 WO2005044186 A3 WO 2005044186A3 US 2004035068 W US2004035068 W US 2004035068W WO 2005044186 A3 WO2005044186 A3 WO 2005044186A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulations
administering
methods
same
inhalable pharmaceutical
Prior art date
Application number
PCT/US2004/035068
Other languages
French (fr)
Other versions
WO2005044186A2 (en
Inventor
Michelle L Dawson
Trevor C Roche
Anthony J Taylor
Mark Whitaker
Owen Chisora Chidavaenzi
Original Assignee
Glaxo Group Ltd
Smithkline Beecham Corp
Michelle L Dawson
Trevor C Roche
Anthony J Taylor
Mark Whitaker
Owen Chisora Chidavaenzi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd, Smithkline Beecham Corp, Michelle L Dawson, Trevor C Roche, Anthony J Taylor, Mark Whitaker, Owen Chisora Chidavaenzi filed Critical Glaxo Group Ltd
Publication of WO2005044186A2 publication Critical patent/WO2005044186A2/en
Publication of WO2005044186A3 publication Critical patent/WO2005044186A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Pharmaceutical formulations suitable for inhalation comprise at least one pharmaceutically active medicament and at least one desiccating agent.
PCT/US2004/035068 2003-10-28 2004-10-22 Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same WO2005044186A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51500203P 2003-10-28 2003-10-28
US60/515,002 2003-10-28

Publications (2)

Publication Number Publication Date
WO2005044186A2 WO2005044186A2 (en) 2005-05-19
WO2005044186A3 true WO2005044186A3 (en) 2007-03-15

Family

ID=34572792

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/035068 WO2005044186A2 (en) 2003-10-28 2004-10-22 Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same

Country Status (1)

Country Link
WO (1) WO2005044186A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1905440A1 (en) * 2006-09-06 2008-04-02 Boehringer Ingelheim Pharma GmbH & Co. KG Use of a pharmaceutical composition comprising an anticholinergic for killing microorganisms and for treating respiratory tract infections
ES2739352T3 (en) 2009-02-26 2020-01-30 Glaxo Group Ltd Pharmaceutical formulations comprising 4 - {(1R) -2 - [(6- {2 - [(2,6-dichlorobenzyl) oxy] ethoxy} hexyl) amino] -1-hydroxyethyl} -2- (hydroxymethyl) phenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
AU2011298315B2 (en) 2010-08-31 2014-08-28 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
EP3461474B1 (en) 2010-08-31 2020-11-11 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
MX2017005692A (en) 2014-10-31 2017-08-07 Glaxosmithkline Ip Dev Ltd Powder formulation.
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
ES2908479T3 (en) 2015-08-26 2022-04-29 Achillion Pharmaceuticals Inc Compounds for the treatment of immune and inflammatory disorders
CN109414441A (en) 2016-06-27 2019-03-01 艾其林医药公司 The quinazoline and benzazolyl compounds for treating medical disorder
JP2021535112A (en) 2018-08-20 2021-12-16 アキリオン ファーマシューティカルズ，インコーポレーテッド Pharmaceutical compounds for the treatment of medical disorders of complement D factor
WO2020081723A1 (en) 2018-10-16 2020-04-23 Georgia State University Research Foundation, Inc. Carbon monoxide prodrugs for the treatment of medical disorders
AU2021276611A1 (en) 2020-05-18 2022-12-15 Orexo Ab New pharmaceutical composition for drug delivery
WO2023094826A1 (en) 2021-11-25 2023-06-01 Orexo Ab Pharmaceutical composition comprising adrenaline

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US6143277A (en) * 1995-04-14 2000-11-07 Glaxo Wellcome Inc. Metered dose inhaler for salmeterol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610163A (en) * 1989-09-16 1997-03-11 Boehringer Ingelheim Gmbh Esters of thienyl carboxylic acids and amino alcohols and their quaternization products
US5837699A (en) * 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
US6143277A (en) * 1995-04-14 2000-11-07 Glaxo Wellcome Inc. Metered dose inhaler for salmeterol

Also Published As

Publication number Publication date
WO2005044186A2 (en) 2005-05-19

Similar Documents

Publication Publication Date Title
ID29181A (en) COMBINATION OF FORMOTEROL AND TIOTROPIUM SALT
WO2006017505A3 (en) Pharmaceutical formulations comprising pleconaril for the treatment of airway diseases
ID30171A (en) FORMOTEROL COMBINATIONS AND FUROAT MOMETASONS FOR ASMA
EP1589947B8 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
IL171683A (en) Immunosuppressant compounds, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for therapy
WO2006008639A8 (en) Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
WO2006022996A3 (en) Dosage form containing multiple drugs
WO2005044178A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2002100390A3 (en) Improved method of treating the syndrome of coronary heart disease risk factors in humans
WO2005046640A3 (en) Multi-site drug delivery platform
WO2005044187A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
SE0102276D0 (en) Device and method for administering a drug
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
WO2004037207A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
WO2005010022A3 (en) Agonist polypeptide of receptor for zot and zonulin
WO2001045715A3 (en) Combinations of an adenosine a1 agonist with an opioid and their use in the treatment of pain
WO2004037199A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
WO2003018535A3 (en) Novel aminobenzoephenones
WO2006124556A3 (en) Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same
WO2004087105A8 (en) Combination formulations of platinum agents and fluoropyrimidines
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
MY141008A (en) Oral formulations of deoxypeganine and their uses
WO2005030132A3 (en) Therapeutic regimens for administering drug combinations
WO2004041181A3 (en) Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration
WO2002041875A3 (en) Method for producing readily soluble medicament formulations and corresponding formulations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase